Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Immuneering Corp (IMRX)

Immuneering names Andrew Gengos CFO, starting on or before July 16, 2026

Neutral Impact 4 of 5 leadership Written later

Immuneering appointed Andrew Gengos as Chief Financial Officer and Treasurer, effective when he starts employment, which is expected on or before July 16, 2026. He succeeds Mallory Morales as principal financial officer, while she remains Senior Vice President Finance and Chief Accounting Officer. The filing describes a $530,000 base salary and a 650,000-share option grant as inducements, which matters to shareholders because it sets the compensation terms for the company's top finance role.

Key points

  • Andrew Gengos was appointed CFO and Treasurer by the Board on June 11, 2026, with employment expected to begin on or before July 16, 2026.
  • Gengos previously served as CFO of Terns Pharmaceuticals from February 2025 to May 2026.
  • Compensation includes a $530,000 annual base salary, a target bonus of 40% of base salary, and an option to purchase 650,000 shares.
  • Mallory Morales will stop serving as principal financial officer but remains Chief Accounting Officer.

The filing

CompanyImmuneering Corp (IMRX)
Form8-K, current report
Filed with the SECJun 15, 2026, 4:12 PM ET
Accession number0001790340-26-000074

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.